EP0598813A4 - Immunostimulation. - Google Patents

Immunostimulation.

Info

Publication number
EP0598813A4
EP0598813A4 EP9292917802A EP92917802A EP0598813A4 EP 0598813 A4 EP0598813 A4 EP 0598813A4 EP 9292917802 A EP9292917802 A EP 9292917802A EP 92917802 A EP92917802 A EP 92917802A EP 0598813 A4 EP0598813 A4 EP 0598813A4
Authority
EP
European Patent Office
Prior art keywords
immunostimulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP9292917802A
Other versions
EP0598813A1 (en
Inventor
Andrew Francis Geczy
Gregory John Russell-Jones
Stephen John Duncan Bell
David Albert Cooper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotech Australia Pty Ltd
St Vincents Hospital Sydney Ltd
Original Assignee
Biotech Australia Pty Ltd
St Vincents Hospital Sydney Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotech Australia Pty Ltd, St Vincents Hospital Sydney Ltd filed Critical Biotech Australia Pty Ltd
Publication of EP0598813A1 publication Critical patent/EP0598813A1/en
Publication of EP0598813A4 publication Critical patent/EP0598813A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
EP9292917802A 1991-08-13 1992-08-10 Immunostimulation. Withdrawn EP0598813A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPK772591 1991-08-13
AU7725/91 1991-08-13
PCT/AU1992/000423 WO1993003762A1 (en) 1991-08-13 1992-08-10 Immunostimulation

Publications (2)

Publication Number Publication Date
EP0598813A1 EP0598813A1 (en) 1994-06-01
EP0598813A4 true EP0598813A4 (en) 1994-09-14

Family

ID=3775617

Family Applications (1)

Application Number Title Priority Date Filing Date
EP9292917802A Withdrawn EP0598813A4 (en) 1991-08-13 1992-08-10 Immunostimulation.

Country Status (10)

Country Link
EP (1) EP0598813A4 (en)
JP (1) JPH07500819A (en)
CA (1) CA2115424A1 (en)
CZ (1) CZ28294A3 (en)
HU (2) HUT70269A (en)
NZ (1) NZ243929A (en)
OA (1) OA09885A (en)
SK (1) SK13494A3 (en)
WO (1) WO1993003762A1 (en)
ZA (1) ZA926021B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6786600A (en) * 1999-08-20 2001-03-19 General Hospital Corporation, The Outer membrane protein a, peptidoglycan-associated lipoprotein, and murein lipoprotein as therapeutic targets for treatment of sepsis
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8010189B2 (en) 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
ES2588705T3 (en) 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Use of liposomes in a vehicle comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20110070298A1 (en) 2008-06-05 2011-03-24 Immunovaccine Technologies Inc. Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance
AU2012321022B2 (en) 2011-10-06 2017-03-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
EP2878335B1 (en) 2013-11-10 2018-01-03 Brainsgate Ltd. Implant and delivery system for neural stimulator
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006590A1 (en) * 1986-04-21 1987-11-05 Bioenterprises Pty. Ltd. Immunopotentiation
WO1992005192A1 (en) * 1990-09-18 1992-04-02 Biotech Australia Pty. Limited T-cell epitopes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0109688A3 (en) * 1982-11-23 1986-12-03 The Wellcome Foundation Limited Improved complexes, processes for obtaining them and formulations containing such complexes
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
DE3483957D1 (en) * 1983-11-21 1991-02-21 Wellcome Found COMPLEX, METHOD FOR THEIR PRODUCTION AND FORMULATIONS CONTAINING THE SAME.
NL8403195A (en) * 1984-10-19 1986-05-16 Nederlanden Staat IMMUNOGENIC COMPLEXES AND VACCINES CONTAINING THESE.
CA1340888C (en) * 1988-09-01 2000-02-01 Algis Anilionis Vaccines and diagnostic assays for haemophilus influenzae

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006590A1 (en) * 1986-04-21 1987-11-05 Bioenterprises Pty. Ltd. Immunopotentiation
WO1992005192A1 (en) * 1990-09-18 1992-04-02 Biotech Australia Pty. Limited T-cell epitopes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
S. CROFT ET AL.: "TraT: A POWERFUL CARRIER MOLECULE FOR THE STIMULATION OF IMMUNE RESPONSES TO PROTEIN AND PEPTIDE ANTIGENS.", JOURNAL OF IMMUNOLOGY., vol. 146, no. 3, 1 February 1991 (1991-02-01), BALTIMORE US, pages 793 - 798 *
See also references of WO9303762A1 *

Also Published As

Publication number Publication date
HUT70269A (en) 1995-09-28
JPH07500819A (en) 1995-01-26
CZ28294A3 (en) 1994-05-18
EP0598813A1 (en) 1994-06-01
SK13494A3 (en) 1994-09-07
CA2115424A1 (en) 1993-03-04
NZ243929A (en) 1994-12-22
OA09885A (en) 1994-09-15
ZA926021B (en) 1993-03-26
WO1993003762A1 (en) 1993-03-04
HU9400233D0 (en) 1994-05-30
HU210605A9 (en) 1995-05-29

Similar Documents

Publication Publication Date Title
DE69107059D1 (en) Sigma-delta-modulator.
ZA92908B (en) Compounds.
AR244753A1 (en) Azo-colouring.
EP0597463A3 (en) Thermotherapiesonde.
EP0580285A3 (en) Auto-reclosers.
DE69111595D1 (en) Squarylium- und crokonyliumfarbstoffe.
DE69104185D1 (en) Luftreservoir.
DE69112211D1 (en) Luftreinigungsvorrichtung.
ZA929517B (en) Compounds.
DE59204008D1 (en) Trachealstent.
ZA926482B (en) Cyanophenylpyrroles.
DE69106281D1 (en) Phenanthrenderivat.
EP0572808A3 (en) Antiblocage-system.
ZA927792B (en) Anti-alpha6-integrin-antibodies.
ZA929590B (en) Diphenylsulphides.
DE69102644D1 (en) Demodulationsreferenzsignalquelle.
ZA926021B (en) Immunostimulation.
EP0576606A4 (en) Residual protease-iii.
DE69110012D1 (en) Linienerkennungsverfahren.
DE69114491D1 (en) Olefincopolymere.
EP0599191A3 (en) Speed-governor-circuit.
DE69205795D1 (en) Mesoprotheseunterlage.
EP0572573A4 (en) Thyroid-derived chondrocyte-stimulating factor.
ZA925185B (en) Dithianes.
DE69203865D1 (en) Thermo-transferdrucksystem.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940304

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19940728

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19960702

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970114